Cardiometabolic multimorbidity is common among patients with psoriasis and is associated with poorer outcomes compared to those without comorbidity. (3rd October 2022)

• Record Type: Journal Article
• Authors: Enos, Clinton W.; Ramos, Vanessa L.; McLean, Robert R.; Lin, Tin-Chi; Foster, Nicole; Dube, Blessing; Van Voorhees, Abby S.
• Is Part Of: Journal of dermatological treatment. Volume 33:Number 7(2022)
• Page Start: 2975
• Page End: 2982
• Publication Date: 2022-10-03
• Subjects: Psoriasis -- multimorbidity -- comorbid disease -- metabolic disease -- biologics -- biologic therapy -- psoriatic disease -- outcomes -- treatment response; Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.1080/09546634.2022.2089329
• Languages: English
• ISSNs: 0954-6634

Abstract

Abstract: Background: Associations between cardiometabolic multimorbidity and response to therapy in psoriasis are unknown. Objective: Determine the associations of multimorbidity with response to biologic treatment in psoriasis patients. Methods: CorEvitas Psoriasis Registry participants who initiated biologic therapy and had 6-month follow-up were stratified by 0, 1, 2+ comorbidities (diabetes, hypertension, hyperlipidemia). Adjusted odds ratios (95% CIs) were calculated overall and separately by biologic class (TNFi, IL-17i, IL-12/23i + IL-23i), to assess the likelihood of achieving response for the 1 and 2+ groups vs. 0. Results: Of 2, 923 patients, 49.5%, 24.7% and 25.8% reported 0, 1 and 2+ comorbidities, respectively. Overall, likelihood of PASI75 was 18% (OR = 0.82; 95%CI: 0.67, 1.00) and 23% (OR = 0.77; 95%CI: 0.63, 0.96) lower in those with 1 and 2+ comorbidities, respectively, vs. 0. In those who initiated IL-17i, odds of PASI75 and PAS90 were 34% (OR = 0.66; 95%CI: 0.48-0.91) and 35% (OR = 0.65; 95%CI: 0.47-0.91) lower in the 2+ multimorbidity cohort. No significant associations were found among users of TNFi or IL-12/23i + IL-23i groups in the multimorbidity group. Limitations: Patients may not be representative of all psoriasis patients. Conclusion: Multimorbidity in psoriasis may decrease the likelihood of achieving treatment response to biologic therapy and should be considered when discussing treatment expectations with patients.